Scarica l'app Stockscreener
1.06
4.50%
-0.05
Dopo l'orario di chiusura:
1.07
0.01
+0.94%
Precedente Chiudi:
$1.11
Aprire:
$1.11
Volume 24 ore:
1.46M
Relative Volume:
0.78
Capitalizzazione di mercato:
$122.27M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.6424
EPS:
-1.65
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
+7.88%
1M Prestazione:
-0.93%
6M Prestazione:
-2.75%
1 anno Prestazione:
-36.53%
Intervallo 1D:
$1.04
$1.115
Intervallo di 1 settimana:
$0.97
$1.13
Portata 52W:
$0.6611
$1.9399
Fate Therapeutics Inc Stock (FATE) Company Profile
Nome
Fate Therapeutics Inc
Settore
Industria
Telefono
858.875.1803
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Confronta FATE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.06 | 128.04M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-01-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Downgrade | Stifel | Buy → Hold |
| 2023-01-06 | Downgrade | Truist | Buy → Hold |
| 2023-01-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-11-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2022-07-28 | Iniziato | Needham | Hold |
| 2022-07-11 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-11 | Ripresa | BMO Capital Markets | Market Perform |
| 2021-12-15 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-11-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Jefferies | Buy |
| 2021-02-26 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-27 | Ripresa | H.C. Wainwright | Neutral |
| 2020-05-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-09 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Reiterato | Mizuho | Buy |
| 2019-12-09 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-06-07 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2019-03-28 | Iniziato | SVB Leerink | Outperform |
| 2019-01-03 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Iniziato | Jefferies | Buy |
| 2018-08-01 | Iniziato | Citigroup | Buy |
| 2018-03-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mostra tutto
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Will Fate Therapeutics Inc. stock benefit from infrastructure spending2025 Market Overview & Fast Gain Stock Trading Tips - ulpravda.ru
Does Fate Therapeutics Inc. stock trade at a discount to peers2025 Sector Review & Expert-Curated Trade Recommendations - ulpravda.ru
Can Fate Therapeutics Inc. stock beat market expectations this quarterNew Guidance & High Accuracy Swing Entry Alerts - ulpravda.ru
Will Fate Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Selloffs & AI Powered Market Entry Ideas - ulpravda.ru
Why Fate Therapeutics Inc. stock could outperform in 20252025 Bull vs Bear & Comprehensive Market Scan Insights - ulpravda.ru
Trend Review: Why Fate Therapeutics Inc stock could outperform in 2025Layoff News & Technical Buy Zone Confirmation - moha.gov.vn
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Fate Therapeutics reports new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving AverageHere's Why - MarketBeat
ETF Watch: Can Fate Therapeutics Inc stock beat market expectations this quarterTrade Exit Summary & Growth Oriented Trading Recommendations - moha.gov.vn
Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky - Yahoo Finance
Is Fate Therapeutics Inc. stock positioned for long term growth2025 EndofYear Setup & Entry Point Confirmation Signals - Улправда
Will Fate Therapeutics Inc. stock keep outperforming rivalsEarnings Trend Report & Safe Swing Trade Setups - Улправда
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from NASDAQ Biotechnology Index - marketscreener.com
Why hedge funds are buying Fate Therapeutics Inc. stockJuly 2025 Spike Watch & Long-Term Growth Plans - Улправда
Cell Therapy Technologies Market Top Players, Segments & Regional Trends by 2034 - Straits Research
Fate Therapeutics Inc (FATE) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Healthy Upside Potential: Fate Therapeutics Inc (FATE) - setenews.com
Fate Therapeutics Inc Stock Analysis and ForecastMarket Profile Overview & Fast Profit Portfolio Plans - earlytimes.in
Fate Therapeutics reports positive lupus treatment data at ASH meeting - Investing.com
Fate Therapeutics reports positive lupus treatment data at ASH meeting By Investing.com - Investing.com Canada
Fate Therapeutics Reports Positive Clinical Updates for FT819 in Systemic Lupus Erythematosus and Introduces Next-Generation CAR T-Cell Programs at ASH Annual Meeting - Quiver Quantitative
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs - The Manila Times
Fate Therapeutics, Inc. Presents Updated Phase 1 Clinical Data of FT819 Off-The-Shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-The-Shelf Car T-Shelf CAR T-Cell Programs - marketscreener.com
Fate Therapeutics Presents Updated Phase 1 Clinical Data of - GlobeNewswire
Fate Therapeutics (NASDAQ:FATE) Stock Passes Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
How Fate Therapeutics Inc. stock valuations compare to rivalsWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
Why Fate Therapeutics Inc. stock remains on buy listsWatch List & Safe Entry Point Identification - Newser
Will Fate Therapeutics Inc. stock benefit from sector rotationJuly 2025 Intraday Action & Verified Swing Trading Watchlists - Newser
Published on: 2025-12-02 03:44:47 - Newser
Fate Therapeutics (FATE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Check Out Fate Therapeutics Inc (FATE)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Fate Therapeutics (NASDAQ:FATE) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 - Quiver Quantitative
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Here's Why We're A Bit Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation - simplywall.st
Cantor Fitzgerald Issues Positive Outlook for FATE Earnings - MarketBeat
Multi factor analysis applied to Fate Therapeutics Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Tools to monitor Fate Therapeutics Inc. recovery probabilityBuy Signal & Growth Oriented Trade Recommendations - newser.com
Automated trading signals detected on Fate Therapeutics Inc.Short Setup & Accurate Buy Signal Alerts - newser.com
Will Fate Therapeutics Inc. stock outperform Nasdaq indexQuarterly Portfolio Report & Precise Entry and Exit Recommendations - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Is Fate Therapeutics Inc. stock undervalued vs historical averagesEarnings Trend Report & Capital Efficient Trade Techniques - newser.com
Exit strategy if you’re trapped in Fate Therapeutics Inc.Portfolio Return Summary & Daily Entry Point Trade Alerts - newser.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Brokerages - MarketBeat
Will Fate Therapeutics Inc. see short term momentumEarnings Risk Summary & Real-Time Volume Spike Alerts - newser.com
Fate Therapeutics Inc Azioni (FATE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):